Reversal of Graft Steatosis After Liver Transplantation: Prospective Study

Transplantation Proceedings

Volumn 41, Issue 9, 2009, Pages 3560-3563

  Li, J ^a   Liu, B ^a   Yan, L N ^a   Zuo, Y X ^a   Li, B ^a   Zeng, Y ^a   Zhang, S F ^a   Li, F G ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT DISEASE; BUDD CHIARI SYNDROME; CONTROLLED STUDY; DISEASE CLASSIFICATION; FATTY LIVER; FEMALE; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER HISTOLOGY; LIVER HYDATID CYST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; WILSON DISEASE;

ADULT; AGED; BIOPSY; BRAIN DEATH; CARCINOMA, HEPATOCELLULAR; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TISSUE DONORS;

EID: 71749108150     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.222     Document Type: Article

References (13)

1. Busuttil R.W., and Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 9 (2003) 651
2. Brandhagen D., Fidler J., and Rosen C. Evaluation of the donor liver for living donor liver transplantation. Liver Transpl 9 (2003) S16
3. Chavin K.D., Fiorini R.N., Shafizadeh S., et al. Fatty acid synthase blockade protects steatotic livers from warm ischemia reperfusion injury and transplantation. Am J Transplant 4 (2004) 1440
4. Angele M.K., Rentsch M., Hartl W.H., et al. Effect of graft steatosis on liver function and organ survival after liver transplantation. Am J Surg 195 (2008) 214
5. Marsman W.A., Wiesner R.H., Rodriguez L., et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 62 (1996) 1246
6. Machicao V.I., Krishna M., Bonatti H., et al. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. Liver Transpl 10 (2004) 599
7. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 8 (2002) 765
8. Cammà C., Bruno S., Di Marco V., et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 43 (2006) 64
9. Johnson S.R., Alexopoulos S., Curry M., et al. Primary nonfunction (PNF) in the MELD era: an SRTR database analysis. Am J Transplant 7 (2007) 1009
10. Verran D., Kusyk T., Painter D., et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 9 (2003) 500
11. Nocito A., El-Badry A.M., and Clavien P.A. When is steatosis too much for transplantation?. J Hepatol 45 (2006) 494
12. McCormack L., Petrowsky H., Jochum W., et al. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg 246 (2007) 940
13. Network TOPaT. http://www.optn.org Accessed May 1, 2006